02197

1.34010.67%
XW

Xiaodong Wang

Non-Executive Director

Dr. Xiaodong Wang, Ph.D. is the Co-Founder and Non-Executive Director of Sichuan Clover Biopharmaceuticals, Inc. since March 16, 2021. He has been Co-Founder & Chairman at SIRONAX. Dr. Wang is a Member of Scientific Advisory Board at TenNor Therapeutics (Suzhou) Limited. He Co-founded BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) in 2010 and had been its Chairman of the Scientific Advisory Board since 2011 and serves as its Member of the Scientific Advisory Board. He serves as Co-Chairman of Scientific Advisory Committee of BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) He has been a Non-Executive Director of BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) since February 8, 2016. Dr. Wang joined the BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) in 2010. Dr. Wang is Non-Executive Director at Clover Biopharmaceuticals, Ltd. since March 16, 2021. Dr. Wang was co-founded the Joyant Pharmaceuticals, Inc. Dr. Wang serves as an investigator at HHMI and held the title of George L. MacGregor Distinguished Chair Professor in Biomedical Science at UT-Southwestern from 1997 to 2010 and its Professor in Biomedical Sciences from 2001 to 2010. He has been Founding Director and Architect of 700-person team at the National Institute of Biological Sciences (NIBS) in Beijing since 2003. He is Foreign associate of Chinese Academy of Sciences. He started his independent research career at Emory University. Dr. Wang returned to UT-Southwestern in 1996, was elected to Howard Hughes Medical Institute (HHMI) in 1997 and became a full professor in 2000. His research centers on the molecular mechanism of programmed cell death, or apoptosis, in human cells. Dr. Wang was elected as a member of the National Academy of Sciences, USA, in 2004. For his work, he has been honored with the Molecular Biology Award from the National Academy of Sciences, USA; Norman Hackerman Award from the Welch Foundation; Paul Marks Prize from Memorial Sloan-Kettering Cancer Center; and Eli Lilly Award from American Chemical Society. Dr. Wang graduated from Beijing Normal University in 1984. He holds PhD in Biochemistry from University of Texas Southwestern Medical Center in 1991 and postdoctoral training at UT-Southwestern. Dr. Wang owns 99% of Wang Investment LLC.

Positions